USPTO Examiner SONG JIANFENG - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18758839STABLE NIMODIPINE PARENTERAL FORMULATIONJune 2024March 2025Allow911NoNo
18643086FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATEApril 2024May 2025Allow1320NoNo
186418454-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUNDApril 2024October 2024Allow610NoNo
186418484-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUNDApril 2024October 2024Allow610NoNo
18616858Cannabinoid PouchMarch 2024February 2025Allow1110NoNo
186165772-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDMarch 2024September 2024Allow610NoNo
186166032-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDMarch 2024August 2024Allow510NoNo
18437368CAPSULE FORMULATIONSFebruary 2024April 2025Abandon1410NoNo
18429916METHODS OF PEST CONTROL IN SOYBEANFebruary 2024June 2025Allow1710NoNo
184262119-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow710NoNo
184260929-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
184215352-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow811NoNo
18396828METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTIONDecember 2023February 2025Abandon1410NoNo
18538502AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOFDecember 2023March 2025Allow1510NoNo
18514306MODIFIED WOUND DRESSINGSNovember 2023November 2024Allow1210NoNo
183877554-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUNDNovember 2023April 2024Allow511NoNo
183872029-(6-FLOURO-2-HYDROXYOUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023January 2024Allow310NoNo
18502663ORAL CANNABINOID PRODUCT WITH LIPID COMPONENTNovember 2023April 2025Allow1711NoNo
18488231CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLDOctober 2023December 2024Allow1410NoNo
184879952-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023November 2024Abandon1331NoNo
183799662-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
18485929VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSOctober 2023March 2025Abandon1710NoNo
18378009Synthesis and Antimicrobial Uses of Dinuclear Silver(I) PyrazolatesOctober 2023January 2025Allow1510NoNo
18474782Perfume CompositionsSeptember 2023December 2024Allow1411NoNo
18474798Perfume CompositionsSeptember 2023March 2025Abandon1811NoNo
18368097PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIERSeptember 2023July 2024Allow1010NoNo
18243299NON-SURFACTANT TYPE OIL-WATER DISPERSION COMPOSITION, NON-SURFACTANT TYPE WATER-OIL DISPERSION COMPOSITION, AND MANUFACTURING METHODS FOR BOTH COMPOSITIONSSeptember 2023October 2024Allow1311NoNo
18236466PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENANAugust 2023May 2025Abandon2111NoNo
18235855PRESERVATION OF PERSONAL CARE COMPOSITIONSAugust 2023January 2025Allow1711NoNo
18341541METHOD FOR DEPOT CREATION DURING TRANSDERMAL DRUG DELIVERYJune 2023December 2024Abandon1810NoNo
18337974METHODS FOR TREATING ALZHEIMER'S DISEASE WITH DONEPEZIL TRANSDERMAL SYSTEMJune 2023March 2025Abandon2010NoNo
18206141NOVEL NANOEMULSIONS COMPRISING FATTY ACID AND N-ACYL DERIVATIVES OF AMINO ACID SALTJune 2023March 2025Allow2121NoYes
18329992METHODS AND COMPOSITIONS FOR TREATING DIABETIC FOOT ULCERSJune 2023January 2025Abandon1901NoNo
18324472METHODS OF PEST CONTROL IN SOYBEANMay 2023March 2024Abandon910NoNo
18319794OPHTHALMIC EMULSIONMay 2023December 2024Allow1911NoNo
18309804SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOFApril 2023March 2024Allow1120NoNo
18303387DRUG DELIVERY SYSTEM FOR TREATING DISEASEApril 2023April 2025Allow2321NoNo
18128922PHARMACEUTICAL FORMULATIONSMarch 2023February 2024Allow1110YesNo
18109349Nutritional SupplementFebruary 2023September 2023Allow700NoNo
18109568Formulations for the Delivery of Autophagy Stimulating TrehaloseFebruary 2023June 2024Allow1611NoNo
18094080ASCORBATE IN THE PREVENTION OF STATIN INDUCED VASCULAR CALCIFICATIONJanuary 2023October 2023Allow1011NoNo
18090128FRAGRANCE COMPOSITIONS CONTAINING NORBORNENE DERIVATIVES FOR PERSONAL CARE PRODUCTSDecember 2022September 2023Allow900NoNo
18085720PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENANDecember 2022March 2024Allow1510NoNo
18011796CONDOMS LUBRICATED WITH ANTIVIRAL LUBRICIOUS COMPOSITIONS CONTAINING LAMBDA-CARRAGEENANDecember 2022March 2024Allow1510NoNo
18062351Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming The SameDecember 2022May 2024Allow1711NoNo
18057554Topical Therapy of Skin Fibrosis and MelanomaNovember 2022May 2025Abandon3041NoNo
17988412Cannabinoid PouchNovember 2022December 2023Allow1310NoNo
17985636COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAMENovember 2022September 2024Abandon2311NoNo
17985748METHOD AND KIT FOR PROVIDING A CUSTOMIZABLE NAIL-BITING AND FINGER SUCKING PREVENTION TREATMENTNovember 2022May 2025Allow3040NoNo
18054055LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATINNovember 2022June 2024Abandon1920NoNo
17982950WATER-SOLUBLE MICROENCAPSULATED CANNABINOID EXTRACT POWDER AND METHOD OF MAKING THE SAMENovember 2022February 2024Abandon1610NoNo
17970639Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning MetOctober 2022October 2023Allow1210NoNo
17970632Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning MetOctober 2022November 2023Allow1310NoNo
17967834PROCESSES FOR PRODUCING PARTICLES OF AT LEAST ONE POLYHYDROXYALKANOATE (PHA)October 2022March 2024Abandon1710NoNo
17963607INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOFOctober 2022March 2025Abandon2920NoYes
17958876VOLATILE OILY COMPOSITIONOctober 2022August 2024Abandon2311NoNo
17935667METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTIONSeptember 2022September 2023Allow1210NoNo
17934727Abiotic Anti-VEGF NanoparticleSeptember 2022November 2023Allow1410NoNo
17934056TRANSDERMAL CARRIERSeptember 2022December 2023Allow1510NoNo
17945221HERBICIDAL COMPOUNDSSeptember 2022April 2024Allow1921NoNo
17929396FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATESeptember 2022March 2024Allow1920NoNo
17878947ACTIVE AGENT-CONTAINING ARTICLESAugust 2022May 2024Abandon2210NoNo
17874818LIPID COMPOSITION FOR THE DELIVERY OF THERAPEUTIC CARGOSJuly 2022December 2024Abandon2831NoNo
17863884DRUG DELIVERY SYSTEMJuly 2022January 2024Allow1910NoNo
17863428SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOFJuly 2022February 2023Allow710YesNo
17861413Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and UseJuly 2022December 2024Abandon2910NoNo
17861210CLEANSING PAD AND COMPOSITION FOR REDUCING TOXINSJuly 2022May 2024Abandon2211NoNo
17758554PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTSJuly 2022July 2023Allow1311YesNo
17850565METHOD FOR PREPARATION OF TISSUE ADHESIVE PATCHESJune 2022July 2023Allow1301NoNo
17850018SOLID DOSAGE FORM OF N-1-PYRROLIDINE-N-5-(3-TRIFLUOROMETHOXY)PHENYL BIGUANIDE AND USES THEREOFJune 2022July 2024Abandon2521NoNo
17835684NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITYJune 2022September 2024Allow2811NoNo
17745937HIGH LOAD DISPERSIONSMay 2022June 2023Allow1310NoNo
17744192POLYMERIC TREATMENT COMPOSITIONSMay 2022January 2024Allow2011NoNo
17726865CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLDApril 2022July 2023Allow1510NoNo
17724650BIOPOLYMER COMPOSITIONS, SCAFFOLDS AND DEVICESApril 2022February 2025Allow3441NoNo
17769834Fungicide MixturesApril 2022April 2025Allow3611NoNo
17767142HAIR TREATMENT COMPOSITIONSApril 2022July 2025Allow3911NoNo
17713608Composition Comprising Cannabis Extracts and Method of Manufacturing SameApril 2022May 2024Abandon2511NoNo
17710972TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENTMarch 2022September 2024Abandon2921NoNo
17705752VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSMarch 2022November 2023Abandon2010NoNo
17656642BIOMEDICAL COMPOSITE MATERIAL AND PREPARATION METHOD THEREFORMarch 2022August 2023Allow1711YesNo
17656643AN ABSORBABLE BIOMEDICAL POLYLACTIC ACID COMPOSITE MATERIAL AND PREPARATION METHOD THEREFORMarch 2022August 2023Allow1711YesNo
17703778CANNABINOID FORMULATION AND METHOD OF MAKING THEREOFMarch 2022September 2024Abandon3011YesNo
17687522METHODS FOR IMPROVING RESPIRATORY SYSTEM HEALTH AND INCREASING THE CONCENTRATION OF HYPOTHIOCYANATE ION IN VERTEBRATE LUNGSMarch 2022January 2024Allow2221NoNo
17677648METHODS AND COMPOSITIONS FOR MAKING AND USING COMPATIBLE INSECTICIDAL PROTEINSFebruary 2022May 2025Allow3810NoNo
17672589PERSONAL CARE SPRAY COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENEFebruary 2022March 2024Abandon2521NoNo
17629160NEAR-INFRARED-SHIELDING MATERIALJanuary 2022June 2025Allow4111NoNo
17579579CANNABINOID POUCHESJanuary 2022October 2022Allow820YesNo
17569913ELASTOMER COATED POWDERSJanuary 2022April 2025Abandon3901NoNo
17568790VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERSJanuary 2022October 2023Abandon2211NoNo
17622861USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTSDecember 2021January 2024Abandon2401NoNo
17551982SHAVING AID COMPRISING A BENEFIT AGENTDecember 2021August 2024Allow3341NoNo
17551512AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOFDecember 2021January 2023Abandon1320YesNo
17545878CAPSULE FORMULATIONSDecember 2021February 2024Allow2621YesNo
17530347EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPYNovember 2021April 2025Abandon4110NoNo
17523334STABLE NIMODIPINE PARENTERAL FORMULATIONNovember 2021April 2024Allow2921NoNo
17516564ANTIBACTERIAL AND/OR ANTIVIRAL TREATMENT COMPOSITION FOR OPTICAL COMPONENTS AND METHOD OF APPLICATIONNovember 2021April 2024Abandon2911NoNo
17513990Synthesis and Antimicrobial Uses of Dinuclear Silver(I) PyrazolatesOctober 2021July 2023Allow2011NoNo
17605074HAIR CONDITIONING COMPOSITIONOctober 2021June 2025Allow4411NoNo
17504706FILLED UNCURED RUBBER COMPOUND FOR LESS LETHAL AMMUNITION AND DRUG-ELUTING ELECTROSPUN FIBER MATOctober 2021August 2024Allow3411YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SONG, JIANFENG.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
21
Examiner Affirmed
14
(66.7%)
Examiner Reversed
7
(33.3%)
Reversal Percentile
48.1%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
102
Allowed After Appeal Filing
25
(24.5%)
Not Allowed After Appeal Filing
77
(75.5%)
Filing Benefit Percentile
30.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SONG, JIANFENG - Prosecution Strategy Guide

Executive Summary

Examiner SONG, JIANFENG works in Art Unit 1613 and has examined 833 patent applications in our dataset. With an allowance rate of 54.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.

Allowance Patterns

Examiner SONG, JIANFENG's allowance rate of 54.6% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SONG, JIANFENG receive 2.15 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SONG, JIANFENG is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.8% benefit to allowance rate for applications examined by SONG, JIANFENG. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 72.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 57% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.8% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 50.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 65.2% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.